Palonosetron
ALOXI
What it isLong-acting second-generation 5-HT3-receptor antagonist; prevention of chemotherapy-induced nausea and vomiting.
Why this oneIts unusually durable receptor effect extends protection into delayed chemotherapy nausea, where older setrons fade.
What limits itIt has little QT effect compared with dolasetron or ondansetron; constipation, headache, and cost remain.
NO BOXED WARNINGS
Principal riskConstipation and headache; cost
Classes and tags
Clinical profile
Mechanism of action: Palonosetron ballicule
